Subcutaneous immunoglobulin (SCIG) ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
11Myasthenia gravis2

11. Myasthenia gravis


Clinical trials : 315 Drugs : 232 - (DrugBank : 77) / Drug target genes : 46 - Drug target pathways : 126
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04728425
(ClinicalTrials.gov)
August 28, 202014/7/2020Subcutaneous Immunoglobulin for Myasthenia GravisEfficacy and Safety of Subcutaneous Immunoglobulin in Patients With Myasthenia GravisMyasthenia GravisDrug: subcutaneous immunoglobulin (SCIG);Drug: intravenous immunoglobulin + subcutaneous immunoglobulin (SCIG)University Health Network, TorontoNULLRecruiting18 Years100 YearsAll30Phase 2Canada
2NCT02100969
(ClinicalTrials.gov)
May 201527/3/2014Open Label Study of Subcutaneous Immunoglobulin (SCIg) in Myasthenia GravisOpen Label Study of Subcutaneous Immunoglobulin (SCIg) in Myasthenia GravisMyasthenia GravisDrug: HIZENTRA ®Mazen Dimachkie, MDCSL BehringCompleted18 YearsN/AAll23Phase 2United States;Canada